[go: up one dir, main page]

MXPA02007632A - Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa. - Google Patents

Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.

Info

Publication number
MXPA02007632A
MXPA02007632A MXPA02007632A MXPA02007632A MXPA02007632A MX PA02007632 A MXPA02007632 A MX PA02007632A MX PA02007632 A MXPA02007632 A MX PA02007632A MX PA02007632 A MXPA02007632 A MX PA02007632A MX PA02007632 A MXPA02007632 A MX PA02007632A
Authority
MX
Mexico
Prior art keywords
protein kinase
kinase inhibitors
urea derivatives
inhibitors
benzothiazolyl urea
Prior art date
Application number
MXPA02007632A
Other languages
English (en)
Inventor
Anna Ericsson
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of MXPA02007632A publication Critical patent/MXPA02007632A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

La presente invencion es dirigida a un compuesto de formula (l), mezclas racemicas-diastereomericas del mismo, isomeros opticos del mismo, promedicamentos del mismo, isotopos del mismo o sales farmaceuticamente aceptables de dicho compuesto, isomeros, promedicamentos e isotopos, en donde las variables son definidas en la presente. Los compuestos de esta invencion son utiles como inhibidores de serina/treonina y tirosina cinasas. En particular, compuestos de esta invencion son utiles como inhibidores de tirosina cinasas, que son importantes en enfermedades hiper-proliferativas, especialmente en cancer y en el proceso de angiogenesis. (ver formula).
MXPA02007632A 2000-02-07 2001-02-06 Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa. MXPA02007632A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18084100P 2000-02-07 2000-02-07
PCT/US2001/003803 WO2001057008A1 (en) 2000-02-07 2001-02-06 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
MXPA02007632A true MXPA02007632A (es) 2004-08-23

Family

ID=22661941

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02007632A MXPA02007632A (es) 2000-02-07 2001-02-06 Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.

Country Status (18)

Country Link
US (1) US7091227B2 (es)
EP (1) EP1254123A1 (es)
JP (1) JP2003521543A (es)
KR (1) KR20020084116A (es)
CN (1) CN1422262A (es)
AR (1) AR030189A1 (es)
AU (1) AU2001236698A1 (es)
BG (1) BG107062A (es)
BR (1) BR0108085A (es)
CA (1) CA2398754A1 (es)
HU (1) HUP0300359A2 (es)
IL (1) IL151045A0 (es)
MX (1) MXPA02007632A (es)
NO (1) NO20023713L (es)
PL (1) PL357099A1 (es)
SK (1) SK12712002A3 (es)
WO (1) WO2001057008A1 (es)
ZA (1) ZA200206235B (es)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
AU8022901A (en) * 2000-08-21 2002-03-04 Pacific Corp Novel thiourea derivatives and the pharmaceutical compositions containing the same
US6492521B2 (en) * 2000-11-03 2002-12-10 Cytec Technology Corp. Hindered amine light stabilizers based on multi-functional carbonyl compounds and methods of making same
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
RU2340605C2 (ru) 2002-06-27 2008-12-10 Ново Нордиск А/С Арилкарбонильные производные в качестве терапевтических средств
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
EP1546156A1 (en) * 2002-08-10 2005-06-29 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
US7056925B2 (en) 2002-08-13 2006-06-06 Abbott Laboratories Urea kinase inhibitors
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7589112B2 (en) * 2002-10-24 2009-09-15 Merck Patent Gmbh Methylene urea derivatives
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
US7582635B2 (en) * 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US7186725B2 (en) * 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
US7390670B2 (en) * 2003-02-20 2008-06-24 Lumigen, Inc. Signalling compounds and methods for detecting hydrogen peroxide
CN1839126A (zh) * 2003-02-28 2006-09-27 拜耳制药公司 用于治疗癌症和其它病症的新的氰基吡啶衍生物
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US7528151B2 (en) * 2003-03-06 2009-05-05 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
US7514562B2 (en) * 2003-03-07 2009-04-07 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0305426D0 (en) * 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
DE602004011340T2 (de) 2003-05-20 2008-11-06 Bayer Healthcare Llc Diaryl-harnstoffe mit kinasehemmender wirkung
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
PL2392565T3 (pl) * 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
US20050165031A1 (en) 2003-11-13 2005-07-28 Ambit Biosciences Corporation Urea derivatives as ABL modulators
JP4834840B2 (ja) 2004-01-06 2011-12-14 ノヴォ ノルディスク アー／エス ヘテロアリール尿素およびグルコキナーゼ活性化剤としてのその使用
JP2007518823A (ja) * 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
FR2868421B1 (fr) 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
ZA200700527B (en) * 2004-07-20 2008-08-27 Siena Biotech Spa Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
KR20070064660A (ko) * 2004-10-07 2007-06-21 베링거 인겔하임 인터내셔날 게엠베하 Ｐｉ３ 키나제
KR20070062998A (ko) * 2004-10-13 2007-06-18 메르크 파텐트 게엠베하 키나제 억제제로서의 복소환 치환된 비스아릴우레아 유도체
AU2005316313B2 (en) * 2004-12-17 2011-09-29 Eli Lilly And Company Novel MCH receptor antagonists
IL172561A0 (en) * 2004-12-30 2006-04-10 Chemagis Ltd Novel process for preparing pramipexole and its optical isomeric mixture by reduction with sodium triacetoxyborohydride
KR20060079098A (ko) * 2004-12-31 2006-07-05 주식회사 엘지생명과학 신규한([1,3]티아졸로[5,4-ｂ]피리딘-2-일)-2-카르복사마이드유도체
US7645778B2 (en) * 2005-01-19 2010-01-12 Bristol-Myers Squibb Company Heteroaryl compounds as P2Y1 receptor inhibitors
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
GB0508471D0 (en) * 2005-04-26 2005-06-01 Celltech R&D Ltd Therapeutic agents
AR056867A1 (es) * 2005-06-27 2007-10-31 Bristol Myers Squibb Co Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
WO2007002635A2 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002634A1 (en) * 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
CA2617788A1 (en) * 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
GB0606429D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Organic compounds
CA2647278A1 (en) * 2006-04-06 2007-10-11 Boehringer Ingelheim International Gmbh Thiazolyldihydroindazole derivatives as protein kinase inhibitors
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
MX2008012535A (es) * 2006-04-06 2008-10-10 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles.
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070259855A1 (en) * 2006-04-06 2007-11-08 Udo Maier Thiazolyl-dihydro-indazole
US7517995B2 (en) 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en) * 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
CA2654212A1 (en) 2006-06-14 2007-12-21 Boehringer Ingelheim International Gmbh New chemical compounds
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
EP1878731B1 (en) * 2006-06-26 2008-08-20 Helm AG Process for producing pramipexole
WO2008001883A1 (fr) * 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. DÉRIVÉ D'ACIDE α-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
US7960569B2 (en) * 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
PT2142529E (pt) 2007-04-27 2014-03-20 Purdue Pharma Lp Antagonistas de trpv1 e as respectivas utilizações
MX2009011601A (es) 2007-04-27 2009-11-10 Purdue Pharma Lp Agentes terapeuticos utiles para tratar el dolor.
EP2162445B1 (en) 2007-06-05 2013-11-27 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
BRPI0813831A2 (pt) * 2007-07-18 2015-01-06 Novartis Ag Compostos de heteroarila bicíclica e seu uso como inibidores de quinase
JP5561702B2 (ja) * 2007-08-02 2014-07-30 アムジエン・インコーポレーテツド Ｐｉ３キナーゼ調節剤および使用方法
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
WO2009111644A2 (en) * 2008-03-05 2009-09-11 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
AR071523A1 (es) * 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2009143584A1 (en) * 2008-05-30 2009-12-03 Vegenics Limited Treatment of pulmonary edema
JP2011525535A (ja) * 2008-06-24 2011-09-22 武田薬品工業株式会社 ＰＩ３Ｋ／ｍＴＯＲ阻害剤
FR2945806B1 (fr) * 2009-05-19 2013-04-05 Sanofi Aventis Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
FR2933980B1 (fr) * 2008-07-18 2011-07-29 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
FR2933982A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
FR2933981A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis NOUVEAUX DERIVES IMIDAZO°1,2-a!PYRIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET NOUVELLE UTILISATION NOTAMMENT COMME INHIBITEURS DE MET
TW201006839A (en) * 2008-07-18 2010-02-16 Sanofi Aventis Novel imidazo[1,2-a]pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
CR20110389A (es) * 2008-12-19 2011-07-13 Abbott Lab Compuestos y métodos de uso
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2576544A4 (en) * 2010-06-01 2013-09-11 Angion Biomedica Corp INHIBITORS OF CYTOCHROMES P450 AND USES THEREOF
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
EP2748172B1 (en) * 2011-09-30 2017-12-06 Kineta, Inc. Anti-viral compounds
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
IN2014CN03597A (es) * 2011-10-14 2015-10-09 Ambit Biosciences Corp
CN103958508B (zh) 2011-10-14 2019-02-12 艾伯维公司 用于治疗癌症以及免疫与自身免疫性疾病的细胞凋亡诱导剂
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
ES2489297B1 (es) * 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
CN105175408B (zh) * 2014-06-04 2018-07-17 中国人民解放军第二军医大学 苯并噻唑类化合物及其作为药物的用途
CN104402875A (zh) * 2014-12-25 2015-03-11 西安山川医药科技有限公司 N-(2-氨基乙基)-n′-(6-取代-2-苯并噻唑基)脲及其盐类化合物的合成方法和用途
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
CN107641118B (zh) * 2016-07-22 2020-11-06 爱科诺生物医药股份有限公司 具有细胞坏死抑制活性的化合物及其组合物和应用
KR101838615B1 (ko) 2016-09-30 2018-03-15 숙명여자대학교산학협력단 신규한 벤조옥사졸 또는 벤조티아졸 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN106632403B (zh) * 2017-01-23 2018-09-11 牡丹江医学院 一种手术用止痛消炎药及其制备方法
WO2018224455A1 (en) 2017-06-07 2018-12-13 Basf Se Substituted cyclopropyl derivatives
PL3692023T3 (pl) * 2017-10-02 2023-12-11 1ST Biotherapeutics, Inc. Związki benzotiazolowe i sposoby ich stosowania w leczeniu zaburzeń neurodegeneracyjnych
CA3084809A1 (en) * 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
US11731985B2 (en) 2018-05-10 2023-08-22 Hb Therapeutics Inc. Compositions and methods for treating cancer
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
CN108570044A (zh) * 2018-07-02 2018-09-25 秦继伟 一种酰胺类化合物及其合成方法和治疗癌症的用途
CN108690013A (zh) * 2018-07-02 2018-10-23 秦继伟 苯并[d]噻唑衍生物及其作为EGFR抑制剂在癌症治疗中的应用
CN108912115A (zh) * 2018-07-02 2018-11-30 秦继伟 一种用于治疗肺癌的egfr酪氨酸激酶抑制剂
CN108997309A (zh) * 2018-07-17 2018-12-14 中国科学技术大学苏州研究院 一种吡唑-4-芳基衍生物的制备方法
EP3866791A2 (en) * 2018-10-17 2021-08-25 Centre national de la recherche scientifique Urea derivatives for treating and/or preventing cancer
JP2022521537A (ja) 2019-02-22 2022-04-08 ファースト・バイオセラピューティクス・インコーポレイテッド イミダゾピリジニル化合物及び増殖性障害の処置のためのその使用
AU2021215396A1 (en) 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
KR102782574B1 (ko) * 2020-03-30 2025-03-19 주식회사 이노큐어테라퓨틱스 벤조티아졸 유도체 화합물
EP4185267A1 (en) 2020-07-24 2023-05-31 Genzyme Corporation Pharmaceutical compositions comprising venglustat
CA3191617A1 (en) * 2020-09-18 2022-03-24 Sumitomo Pharma Co., Ltd. Novel amine derivatives
WO2022059778A1 (ja) * 2020-09-18 2022-03-24 カルナバイオサイエンス株式会社 環状ウレア誘導体
JPWO2023008472A1 (es) * 2021-07-28 2023-02-02
CZ310416B6 (cs) * 2023-12-15 2025-05-28 Univerzita Hradec Králové 1-(3-Chlor-4-hydroxyfenyl)-3-(6-((trifluormethyl)thio)benzo[d]thiazol-2-yl)močovina pro použití pro léčbu rakoviny

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3810988A (en) * 1968-11-01 1974-05-14 Ciba Geigy Ag Control of phytopathogenic fungi with n-benzothiazae-2-yl n-{40 {11 propylure
CH505543A (de) * 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
JPS53124265A (en) 1977-04-06 1978-10-30 Nippon Tokushu Noyaku Seizo Kk Urea or thiourea type compounds, their preparation and insecticides contaning the same as active agent
JPS57175189A (en) 1981-04-21 1982-10-28 Kyowa Hakko Kogyo Co Ltd Benzothiazole derivative and its preparation
US4966849A (en) * 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
JPS62187842A (ja) 1985-10-25 1987-08-17 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
JPH0662650B2 (ja) 1990-04-02 1994-08-17 ファイザー・インコーポレーテッド チロシンキナーゼ阻害剤としてのベンジルホスホン酸
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
ES2108120T3 (es) 1991-05-10 1997-12-16 Rhone Poulenc Rorer Int Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
FI935279L (fi) 1991-05-29 1993-11-26 Pfizer Tricykliska polyhydroxyltyrosinkinasininhibitorer
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
SK283413B6 (sk) 1992-08-06 2003-07-01 Warner-Lambert Company 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
BR9207175A (pt) 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
UA54427C2 (uk) 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
EA001779B1 (ru) 1996-05-01 2001-08-27 Эли Лилли Энд Компани Способ лечения заболеваний, связанных с фактором роста сосудистого эндотелия
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
TW513418B (en) 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
DK0956339T3 (da) 1996-08-23 2006-01-30 Licentia Oy Rekombinant vaskulær endotelcellevækstfaktor D (VEGF-D)
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
JPH11130761A (ja) * 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
IL135176A0 (en) * 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
JPH11222431A (ja) 1998-01-30 1999-08-17 Otsuka Pharmaceut Co Ltd 医薬組成物
WO2001007411A1 (fr) 1999-07-26 2001-02-01 Banyu Pharmaceutical Co., Ltd. Derives de biaryluree

Also Published As

Publication number Publication date
JP2003521543A (ja) 2003-07-15
AR030189A1 (es) 2003-08-13
CA2398754A1 (en) 2001-08-09
IL151045A0 (en) 2003-04-10
BR0108085A (pt) 2003-03-18
NO20023713L (no) 2002-10-04
ZA200206235B (en) 2004-02-13
HUP0300359A2 (hu) 2003-06-28
PL357099A1 (en) 2004-07-12
WO2001057008A1 (en) 2001-08-09
SK12712002A3 (sk) 2003-02-04
KR20020084116A (ko) 2002-11-04
NO20023713D0 (no) 2002-08-06
BG107062A (bg) 2003-04-30
US20030153568A1 (en) 2003-08-14
EP1254123A1 (en) 2002-11-06
CN1422262A (zh) 2003-06-04
US7091227B2 (en) 2006-08-15
AU2001236698A1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
MXPA02007632A (es) Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
MXPA02005844A (es) Inhibidores de cinasas de proteina.
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
ATE400274T1 (de) Hemmstoffe der akt aktivität
MY138352A (en) Benzothiazole derivatives
ATE512957T1 (de) Hemmer der akt aktivität
ATE475652T1 (de) Chinazolinderivate
DK1678166T3 (da) Proteinkinaseinhibitorer
MXPA03010961A (es) Compuestos de tiazol utiles como inhibidores de proteinas cinasas.
ATE503483T1 (de) Hemmer der akt aktivität
ATE446752T1 (de) Hemmer der akt aktivität
ATE461179T1 (de) Hemmer der akt aktivität
NZ508268A (en) Bicyclic pyrimidines and bicyclic 3,4- dihydropyrimidines as inhibitors of cellular proliferation
BG106585A (en) Kinase inhibitors as therapeutic agents
NO20032801L (no) Tiazolderivater for behandling av PPAR-relaterte forstyrrelser
MY143400A (en) 2-pyridone derivatives as neutrophil elastase inhibitors and their use
DK1240165T3 (da) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamid-inhibitorer af cyclinafhængige kinaser
MY157949A (en) Thioxanthine derivatives as myeloperoxidase inhibitors
MX2007013624A (es) Inhibidores de proteina cinasa.
SE0301232D0 (sv) Novel use
ATE240328T1 (de) Substituierte azaoxindolederivate
GEP20063751B (en) 2-Acyl Indol Derivatives and Their Use as Anti-Tumour Agents
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer&#39;s disease
PT1270570E (pt) Composto de amida e sua utilizacao